Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference

February 7, 2024

https://www.globenewswire.com/news-release/2024/02/07/2825163/0/en/Jasper-Therapeutics-to-Present-at-the-Oppenheimer-34th-Annual-Healthcare-Conference.html

REDWOOD CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq:JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced that management will present at the Oppenheimer 34th Annual Healthcare Conference at 4:40pm EST on February 13, 2024. The conference is being held in a virtual format.

Read more at globenewswire.com

Related news for (JSPR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.